Zylox-Tonbridge and Defu Capital take 16.7% of Lifetech for HK$1.48bn
Zylox-Tonbridge and Defu Capital will take 16.7% of Lifetech Scientific for HK$1.48bn, combining four segments of vascular intervention in one platform and planning a full merger within a year.
Image: China Ventures
The context
China's device market has been reshaped by volume-based procurement, which cuts prices in exchange for guaranteed hospital volumes. Specialists with one product line have seen revenue fall and margins compress; platforms with a broader portfolio can spread the discount across more categories.
Zylox and Lifetech are complementary rather than overlapping: one is strong in peripheral and neurovascular, the other in aortic and structural heart. Together they cover the four segments hospitals buy together.
The counter-argument
The bear case is that breadth does not fix a price war. If procurement keeps cutting, a larger platform simply loses more revenue per procedure, and the combined company inherits Lifetech's 11.2% decline and RMB34.4m loss.
There is also a deal-structure risk. A 16.7% stake with an intention to merge in nine to twelve months is not a binding commitment, and the exchange ratio will be negotiated when both sides know more about Lifetech's 2026 numbers.
What happens next
Watch the merger agreement and the next procurement round. If the combined group wins multi-segment hospital contracts, the platform logic holds; if prices fall faster than volume rises, scale will not save the margin.
We use essential cookies to keep you signed in, secure forms and remember your session. We do not use advertising or analytics cookies. Read our privacy policy.